KR970061252A - 비-심장 허혈증과 관련된 조직 손상을 감소시키기 위한 약제학적 조성물 - Google Patents

비-심장 허혈증과 관련된 조직 손상을 감소시키기 위한 약제학적 조성물 Download PDF

Info

Publication number
KR970061252A
KR970061252A KR1019970006780A KR19970006780A KR970061252A KR 970061252 A KR970061252 A KR 970061252A KR 1019970006780 A KR1019970006780 A KR 1019970006780A KR 19970006780 A KR19970006780 A KR 19970006780A KR 970061252 A KR970061252 A KR 970061252A
Authority
KR
South Korea
Prior art keywords
tissue
pharmaceutical composition
reductase inhibitor
aldose reductase
day
Prior art date
Application number
KR1019970006780A
Other languages
English (en)
Inventor
토마스 에이 베이어
델빈 알 쥬니어 나이트
바나바라 엘 밀러리
피터 제이 오우츠
에릭 알 페리퍼
웨인 알 트레시
Original Assignee
스피겔 알렌 제이
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스피겔 알렌 제이, 화이자 인코포레이티드 filed Critical 스피겔 알렌 제이
Publication of KR970061252A publication Critical patent/KR970061252A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01021—Aldehyde reductase (1.1.1.21), i.e. aldose-reductase

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

본 발명은 알도오즈 환원 효소 억제제 또는 이의 약제학적으로 허용가능한 염을 약제학적으로 허용가능한 부형제 또는 희석제와 함께 포함하는, 허혈증으로 인한 비-심장 조직 손상을 감소시키기 위한 약제학적 조성물에 관한 것이다.

Description

비-심장 허혈증과 관련된 조직 손상을 감소시키기 위한 약제학적 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (20)

  1. 알도오즈 환원 효소 억제제 또는 이의 약제학적으로 허용가능한 염을, 약제학적으로 허용가능한 부형제 또는 희석제와 함께 포함하는, 포유동물의 허혈증으로 인한 비-심장 조직 손상을 감소시키기 위한 약제학적 조성물.
  2. 제1항에 있어서, 조직이 뇌, 간, 신장, 폐, 장, 골격근, 비장, 췌장, 망막 조직 또는 장 조직인 약제학적 조성물.
  3. 제2항에 있어서, 포유동물이 사람인 약제학적 조성물.
  4. 제3항에 있어서, 조직이 뇌 조직인 약제학적 조성물.
  5. 제3항에 있어서, 조직이 간 조직인 약제학적 조성물.
  6. 제3항에 있어서, 조직이 신장 조직인 약제학적 조성물.
  7. 제3항에 있어서, 조직이 폐 조직인 약제학적 조성물.
  8. 제3항에 있어서, 조직이 장 조직인 약제학적 조성물.
  9. 제3항에 있어서, 조직이 골격근 조직인 약제학적 조성물.
  10. 제3항에 있어서, 조직이 비장 조직인 약제학적 조성물.
  11. 제3항에 있어서, 조직이 췌장 조직인 약제학적 조성물.
  12. 제3항에 있어서, 조직이 망막 조직인 약제학적 조성물.
  13. 제3항에 있어서, 알도오즈 환원 효소 억제제가 약 0.1㎎/㎏/일 내지 약 100㎎/㎏/일의 유효량으로 포함되는 약제학적 조성물.
  14. 제13항에 있어서, 알도오즈 환원 효소 억제제가 예방용으로 투여되는 약제학적 조성물.
  15. 제13항에 있어서, 알도오즈 환원 효소 억제제가 만성적으로 투여되는 약제학적 조성물.
  16. 제3항에 있어서, 알도오즈 환원 효소 억제제가 1-프탈라진아세트산, 3,4-디하이드로-4-옥소-3-[[5-(트리플루오로메틸)-2-벤조티아졸릴]메틸-인 약제학적 조성물.
  17. 제16항에 있어서, 유효량이 약 0.1㎎/㎏/일 내지 약 100㎎/㎏/일인 약제학적 조성물.
  18. 제17항에 있어서, 조직이 골격근 또는 망막 조직인 약제학적 조성물.
  19. 제3항에 있어서, 조직이 장 조직인 약제학적 조성물.
  20. 제17항에 있어서, 사람이 당뇨병을 갖는 약제학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970006780A 1996-02-29 1997-02-28 비-심장 허혈증과 관련된 조직 손상을 감소시키기 위한 약제학적 조성물 KR970061252A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1270796P 1996-02-29 1996-02-29
US60/012,707 1996-02-29

Publications (1)

Publication Number Publication Date
KR970061252A true KR970061252A (ko) 1997-09-12

Family

ID=21756300

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970006780A KR970061252A (ko) 1996-02-29 1997-02-28 비-심장 허혈증과 관련된 조직 손상을 감소시키기 위한 약제학적 조성물

Country Status (14)

Country Link
US (1) US6127367A (ko)
EP (1) EP0792643B1 (ko)
JP (1) JPH09316003A (ko)
KR (1) KR970061252A (ko)
CN (1) CN1081460C (ko)
AT (1) ATE216239T1 (ko)
AU (1) AU724327B2 (ko)
CA (1) CA2198564C (ko)
DE (1) DE69711972T2 (ko)
DK (1) DK0792643T3 (ko)
ES (1) ES2172748T3 (ko)
IL (1) IL120264A0 (ko)
PT (1) PT792643E (ko)
ZA (1) ZA971717B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024053761A1 (ko) * 2022-09-07 2024-03-14 애니머스큐어 주식회사 알도오즈 환원효소 억제제를 포함하는 근원 세포 증식 및 분화 촉진용 조성물

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0982306A3 (en) * 1998-08-21 2000-07-05 Pfizer Products Inc. Polymorph of zopolrestat monohydrate
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2002098421A1 (en) * 2001-06-05 2002-12-12 University Of Maryland, Baltimore Novel treatment for neurological and psychiatric disorders
AU2003229953A1 (en) 2002-04-30 2003-11-17 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
CA2633481C (en) * 2005-12-16 2013-12-17 Sanwa Kagaku Kenkyusho Co., Ltd. Preventive or therapeutic agent for acute renal failure
EP1987829A4 (en) * 2006-02-20 2009-07-29 Sanwa Kagaku Kenkyusho Co PROPHYLACTIC OR THERAPEUTIC AGENT FOR LESIONS DUE TO BRAIN ISCHEMIA OR LESIONS DUE TO BRAIN ISCHEMIA WITH REPERFUSION IN BRAIN VASCULAR ACCIDENTS
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
KR20090104014A (ko) * 2007-01-31 2009-10-05 가부시키가이샤산와카가쿠켄큐쇼 망막신경 또는 시신경의 보호제
WO2008118844A1 (en) 2007-03-23 2008-10-02 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibitors
AU2008299721A1 (en) 2007-09-14 2009-03-19 Astrazeneca Ab Phthalazinone derivatives
CN101821242B (zh) 2007-10-17 2013-07-24 库多斯药物有限公司 4-[3-(4-环丙烷羰基-哌嗪-1-羰基)-4-氟-苄基]-2h-酞嗪-1-酮
CA2705376A1 (en) * 2007-11-15 2009-05-22 Universite Laval Methods for the regulation of the prostaglandin f synthase (pgfs) activity of akr1b1 and uses thereof
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
LT2346495T (lt) 2008-10-07 2016-10-10 Astrazeneca Uk Limited Farmacinė kompozicija 514
US8785483B2 (en) 2010-12-23 2014-07-22 The Board Of Regents Of The University Of Texas System Methods for treating COPD
WO2018075192A1 (en) 2016-10-19 2018-04-26 Spectrum Brands, Inc. Portable steam generator base for iron
WO2022197487A1 (en) 2021-03-18 2022-09-22 Banavara MYLARI Combination of aldose reductase inhibitors and probenecid for the treatment of diabetic complications

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4492706A (en) * 1983-08-01 1985-01-08 American Home Products Corporation Method of lowering lipid levels
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
EP0310931A3 (en) * 1987-10-08 1990-10-03 Ethyl Corporation Poultry feed
FR2665440B1 (fr) * 1990-07-31 1994-02-04 Lipha Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant.
US5064830A (en) * 1990-08-02 1991-11-12 Pfizer Inc. Lowering of blood uric acid levels
JP3049284B2 (ja) * 1990-11-07 2000-06-05 株式会社三和化学研究所 ヒダントイン誘導体並びにそれを有効成分とする糖尿病合併症及び循環器系疾患の予防及び治療剤
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
US5834466A (en) * 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
AU711080B2 (en) * 1994-12-22 1999-10-07 Regents Of The University Of California, The Method for protecting the heart from ischemia
CZ293016B6 (cs) * 1995-06-01 2004-01-14 Sankyo Company Limited Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024053761A1 (ko) * 2022-09-07 2024-03-14 애니머스큐어 주식회사 알도오즈 환원효소 억제제를 포함하는 근원 세포 증식 및 분화 촉진용 조성물

Also Published As

Publication number Publication date
JPH09316003A (ja) 1997-12-09
PT792643E (pt) 2002-08-30
CN1081460C (zh) 2002-03-27
AU724327B2 (en) 2000-09-14
CN1168794A (zh) 1997-12-31
EP0792643A1 (en) 1997-09-03
CA2198564A1 (en) 1997-08-29
EP0792643B1 (en) 2002-04-17
CA2198564C (en) 2000-06-27
DE69711972D1 (de) 2002-05-23
MX9701533A (es) 1998-06-30
ATE216239T1 (de) 2002-05-15
AU1501097A (en) 1997-09-04
DK0792643T3 (da) 2002-07-22
ZA971717B (en) 1998-08-27
DE69711972T2 (de) 2002-08-29
ES2172748T3 (es) 2002-10-01
US6127367A (en) 2000-10-03
IL120264A0 (en) 1997-06-10

Similar Documents

Publication Publication Date Title
KR970061252A (ko) 비-심장 허혈증과 관련된 조직 손상을 감소시키기 위한 약제학적 조성물
BR0213079A (pt) Forma de dosagem para o tratamento da diabetes mellitus
BR9611015A (pt) Composto, composição farmacêutica e processo para o tratamento de uma doença inflamatória suscetìvel ao tratamento com um agente não-tóxico anti-inflamatório não-esteróide, sal farmaceuticamente aceitável, utilização de um composto
KR930003912A (ko) 울혈성 심장 마비 치료법
BR9406979A (pt) Composto,composicão farmaceutica para tratar uma doenca inflamatória suscetivel de tratamento com um agente anti- inflamatório nao esteroidal processos para tratar uma doenca inflamatória e para preparar um composto sal famacéuticamente aceitável uso de um composto composicão farmaceutica anti-inflamatória nao esteroidal
BRPI0618380A2 (pt) combinação farmacêutica e seu uso
BR0014525A (pt) Processo de tratamento de distúrbios metabólicos, especialmente diabetes, ou uma doença ou condição associada com diabetes
RU94041223A (ru) Средство для лечения мотонейроновых заболеваний
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
RS49918B (sr) Upotreba glp-1, ili analoga za lečenje infarkta miokarda
DE59402222D1 (de) Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
AU9125798A (en) Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
KR970027098A (ko) 프로피오페논 유도체 및 이의 제조 방법
BR9911779A (pt) Benzotiofenos, benzofuranos e indóis úteis no tratamento de resistência à insulina e hiperglicemia
KR970704429A (ko) 심혈관 질환의 치료를 위한 드롤록시펜의 용도(use of droloxifene for the treatment of cardiovascular diseases)
BR9910371A (pt) Composto, composição farmacêutica, agente para controlar os receptores relacionados com a retinóide, processos de prevenção e terapia da diabetes mellitus, de prevenção e terapia da hiperlipemia, para acentuar uma sensibilidade à insulina, para melhorar uma resistência à insulina, de prevenção e terapia da tolerância à glicose prejudicada, de prevenção e terapia de uma doença inflamatória, de prevenção de uma esclerose arterial, e, uso do composto
KR950703953A (ko) 2-아미노-6-n-프로필아미노-4, 5, 6, 7-테트라하이드로벤조티아졸(프라미펙솔)의 항우울제로서의 용도(Use of 2-amino-6-n-propylamino-4, 5, 6, 7-tetrahydrobenzothiazole (pramipexol)as an antidepressant drug)
MX9204637A (es) Nuevos derivados de pirazina y procedimiento para su preparacion.
NZ516290A (en) Substituted phenoxyacetic acids
KR870007118A (ko) 광학적으로 순수한 화합물 및 그의 제조 방법
BR0013252A (pt) Micofenolato mofetila em associação com peg-ifn-alfa
KR910019623A (ko) 상승병용을 이용한 안고혈압 치료
WO2001081328A3 (en) Thiazolidinedione analogues and their use for the treatment of diabetes
BR9810292A (pt) Tratamento de diabete com tiazolidinadiona, secretagogo de insulina e inibidor de alfa-glicosidase
KR910019621A (ko) 상승병용을 이용한 안고혈압 치료

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
B601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 19990529

Effective date: 20001230